Single gene disorders come into focus - again by Ropers, Hans-Hilger
or more than 10 years, genome research has
focused on finding genetic risk factors for common dis-
orders, based on the “common disease—common vari-
ant (CDCV)” hypothesis—the intuitive but unproven
assumption that for most of the common disorders like
dementia, diabetes, coronary heart disease, autism, and
hypertension, there are common genetic risk factors.
Since 2007, after many years of growing frustration with
the disappointing results of genome-wide association
studies (GWAS), associated markers were identified for
a wide variety of complex disorders; this was hailed as a
decisive breakthrough in this field. However, these asso-
ciations were only found after massively increasing
cohort sizes and marker densities, meaning that the vast
majority of the associated risk factors have small effects
and that they are of no diagnostic and prognostic rele-
vance. Moreover, many markers were found to be
located in noncoding sequences, and thus, very few pro-
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In the early 1990s, when the second 5-year plan for the Human Genome Project—which requested more money than
any previous research project in biology—was written, common disorders were presented as the future target of
genome research. This was a clever move to ensure continued public support for this endeavor, which had been justi-
fied previously by the prospect that it would lead to the diagnosis, prevention, and therapy of severe, but mostly rare,
Mendelian disorders. Today, more than 15 years later, after billions of dollars have been spent on genome-wide asso-
ciation studies (GWAS), very few major genetic risk factors for common diseases have been identified, and the enthu-
siasm for large GWAS is dwindling. At the same time, there is renewed interest for studying single gene disorders,
which are now considered by some as a better clue to the understanding of common diseases. While this is probably
true, Mendelian disorders are also important in their own right, since they must be far more common than gener-
ally thought. As discussed here, various efficient strategies exist for the elucidation of single gene defects, and their
systematic application in combination with novel genome partitioning and massive parallel sequencing techniques,
will have far-reaching implications for health care.
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mechanisms. Ironically, therefore, very shortly after this
“breakthrough,” there is growing support for the notion
that for most common disorders, the CDCV hypothesis
must be wrong.
1,2
This is certainly true for mental retardation (MR)—the
biggest unsolved problem of clinical genetics and the
largest socioeconomic burden of health care—where
most severe forms are due to defined chromosomal
abnormalities or single gene defects, instead of resulting
from multifactorial inheritance, ie, the interaction of
many different gene variants and environmental factors.
However, there is increasing evidence that single gene
defects also play a significant, previously underesti-
mated, role in other complex disorders. This has led to
growing uneasiness about the validity of the idea that
GWAS is the preferred approach for identifying
sequence variants in the human genome that predispose
to, or cause, disease. Moreover, it has raised serious
doubts about the strategy, first proposed in the early
1990s and uncritically adopted by leading genome cen-
ters worldwide, to focus exclusively on complex disor-
ders. 
After the introduction of massive parallel next-genera-
tion sequencing techniques, there are now indications for
a paradigm shift in this field, with a renewed focus on
single gene disorders. At a recent meeting,
3 two groups
reported on their efforts to unravel the molecular basis
of Mendelian disorders by sequencing all exons in the
genomes of patients and their unaffected parents.
Moreover, leading genome researchers expressed their
belief that instead of GWAS, whole genome sequencing-
based, large-scale elucidation of single gene disorders
will be the strategy of choice for shedding more light on
the molecular architecture of common disorders. 
In the late 1980s, before common disorders were pro-
claimed as the central target of genome research, along
with overly optimistic assumptions about the medical
implications of this research, the revolutionary and
costly project to elucidate the structure of the human
genome had been justified by the prospect that it
would lead to unambiguous diagnosis, prevention, and,
eventually, therapies for severe Mendelian disorders.
Now, almost 20 years after the official commencement
of the Human Genome Project, and 6 years after its
completion, it appears that genome research is coming
around full circle by once again focusing on single gene
defects.
Single gene defects are important 
for health care
Single gene defects have significance in their own right.
In contrast to many complex disorders such as type 2
diabetes and obesity, which are lifestyle-related, become
manifest only later in life, or are relatively mild, single
gene disorders are mostly severe, early-onset conditions,
necessitating lifelong care and support. Moreover, single
gene disorders are far more numerous than generally
assumed, and as a group, they are certainly not rare. 
According to OMIM, the comprehensive catalogue of
human traits that are inherited in a Mendelian fashion
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim),
only slightly more than 2500 human genes have been
linked to disease, and there are approximately 3500
Mendelian diseases for which the molecular cause is not
yet known. It is likely, however, that this is a wide under-
estimate, and that the number of genes which are indis-
pensable for normal embryonic and postnatal develop-
ment, homeostasis, and aging is much higher. 
In mice with induced defects of single genes (ie,
“knockout mice”), conspicuous (disease) phenotypes
or embryonic lethality are the rule rather than the
exception, as discussed elsewhere.
2 In humans, the pro-
portion of gene defects that are associated with recog-
nizable disorders must be even higher, because rela-
tively subtle (eg, behavioral) abnormalities are readily
detectable in man, even without specific clinical exam-
ination. Milder mutations in the same genes known to
cause embryonic lethality when affected by loss-of-
function mutations may be compatible with life but
also cause disease.
Functional considerations and empirical data from
model organisms suggest that most disease-associated
gene defects are inherited as recessive traits. At least in
Western societies, this means that most patients will be
isolated cases, due to small family sizes and the fact that
in these populations, parental consanguinity is rare. In
sporadic cases without specific, previously described
combinations of clinical symptoms, single gene defects
are unlikely to be considered as the underlying cause. In
particular, this holds for patients with complex disorders
and presumed multifactorial inheritance. Thus, as dis-
cussed for MR, it is likely that many Mendelian disor-
ders have not been identified yet because in the well-
studied Western populations, they do not segregate in
families. Irrespective of family sizes and parental con-
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inant disorders conferring a significant reproductive dis-
advantage (eg, severe mental handicaps). Most of these
patients will carry new mutations and therefore will be
isolated cases as well.
For most common diseases, the possibility that there is a
sizable “contamination” by monogenic forms has not
been excluded, and the proportion of cases that are due
to single gene defects is hitherto unknown. As indicated
above, this does not hold for MR, however. Prompted by
the early observation that males are more often affected
than females,
4 and by the description of several large
families where MR segregated in an X-linked fashion
(see ref 5, for example), the hypothesis that single gene
defects on the X chromosome play a major role in MR
was put forward in the early 1970s.
6,7
Since the 1990s, genetic research into the molecular
causes of MR has focused on X-chromosomal genes,
8
and at the time of writing (September 2009), mutations
in 90 X-chromosomal genes have been implicated in
Mendelian forms of MR, demonstrating that this condi-
tion is extremely heterogeneous. Surprisingly, screening
of several hundred families with X-linked MR (XLMR)
has revealed that these 90 genes account for at most
50% of all mutations
9; see also ref 10. This means that
there must be many more genes on the X chromosome
which are indispensable for the normal function of the
human brain. The X chromosome carries about 4% of
all human genes, and even though there is evidence sug-
gesting that on the X, the density of MR genes is higher
than on autosomes,
11 extrapolation of these data suggests
that defects in several thousand human genes may give
rise to cognitive dysfunction. However, the systematic
search for these autosomal MR genes has only just
begun, as discussed below. 
There is increasing evidence that single gene defects also
have important roles in the etiology of other complex
disorders. For example, several homozygous deletions
were recently described in autistic offspring of healthy
consanguineous parents,
12 strongly suggesting that auto-
somal recessive gene defects are important causes of
autism, too. In view of the growing molecular evidence
that MR, autism, and schizophrenia are etiologically
related,
2,13 it is likely that many cases of schizophrenia
are also due to a variety of single gene defects. There is
reason to believe that the same holds true for many
other complex diseases that are generally considered
multifactorial.
14
Systematic elucidation of 
single gene disorders
There are various efficient strategies for elucidating the
molecular defects underlying Mendelian disorders, as
discussed in detail elsewhere.
2 Most of them consist of
two steps, the chromosomal and regional mapping of the
relevant defect and the search for mutations in posi-
tional and functional candidate genes. 
Disease-associated balanced chromosome 
rearrangements 
Systematic breakpoint mapping and cloning in patients
with disease-associated balanced chromosome rearrange-
ments (DBCRs) has been employed by several groups to
identify genes that are truncated or inactivated by the
rearrangement (Figure 1a). Most de novo balanced chro-
mosome rearrangements can be identified by conven-
tional karyotyping, and, with an incidence of 1 in 2000,
they are not rare. About 6% of these are associated with
MR or other clinical abnormalities, which means that in
the European Union, with its 495 million inhabitants,
there must be almost 15 000 patients with de novo
DBCRs, and even more familial cases. So far, only a small
percentage of these patients have been identified, which
argues for systematic karyotyping in all patients where a
genetic cause of the disorder cannot be ruled out.
Unfortunately, however, the ongoing substitution of con-
ventional karyotype analyses with array CGH techniques
(see below) means that balanced chromosome rearrange-
ments will no longer be detected upon routine cytoge-
netic examination.
Mapping of chromosomal breakpoints has been facili-
tated by the availability of an ordered set of large over-
lapping genomic clones that serve as probes for fluo-
rescent in situ hybridization (FISH). Still, determining
the precise sequence of the breakpoint region
remained quite time-consuming. Recently, Chen et al
15
have overcome this problem by preparative sorting of
derivative chromosomes followed by next-generation
sequencing in three mentally retarded patients with
DBCRs, which enabled the identification of three novel
candidate genes for MR. In follow-up studies, they
showed that it is even possible (by paired-end sequenc-
ing) to identify breakpoint-spanning DNA fragments
in total genomic DNA, ie, without prior sorting of chro-
mosomes.
16
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Small deletions, barely detectable by high-resolution
karyotyping, illuminated the way to pinpointing the
Duchenne muscular dystrophy gene
17; later on,
microdeletions were instrumental in the identification of
many other disease genes. Through the recent introduc-
tion of array-based comparative genomic hybridization
(array CGH), screening of the entire human genome for
submicroscopic copy number variants (CNVs) has
become possible, thereby providing a very powerful new
strategy for finding the molecular defects underlying
Mendelian disorders (Figure 1b). Employing tiling path
BAC arrays or, more recently, high-density oligonu-
cleotide arrays, apparently causative de novo microdele-
tions or duplications can be found in more than 10% of
mentally retarded patients,
18 which means that these
small variations are about as common as chromosome
rearrangements that can be seen under the microscope.
Recurrent CNVs that are flanked by low-copy repeats
account for about half of the cases (B. de Vries,
Nijmegen, personal communication, 2009), and for many
of these new “genomic disorders,” 
19 both deletions and
duplications have been observed. 
Apart from CNVs causing disease, eg, by disturbing the
stoichiometry of protein complexes or by unmasking
recessive gene defects,
20 the vast majority of CNVs occur
in healthy individuals, and most of them are functionally
neutral polymorphisms. Using tiling oligonucleotide
microarrays to detect CNVs greater than 450 basepairs,
Conrad et al
21 have identified, on average, more than
1000 validated CNVs when comparing genomes of two
unrelated individuals. 
However, not all CNVs can be assigned unambiguously
to one of these two groups. There is a third category of
CNVs which are neither functionally neutral nor strictly
pathogenic; they are significantly more common in
patients with specific disorders than in healthy individ-
uals. One of the first CNVs of this kind observed, a
recurrent, sometimes familial 1 to 2 Mb deletion/dupli-
cation on chromosome 16p13, was detected in a cohort
of 300 patients with autism spectrum disorder and/or
MR.
22 Follow-up studies
23 have shown that this CNV, and
another on chromosome 15q11.2, are among the most
common and important risk factors for MR and autism
known to date, both raising the risk for these diseases
about 5-fold. Moreover, according to a recent report, the
dup16p13.1 is also a significant risk factor for schizo-
phrenia.
13This CNV encompasses the NDE1 gene, which
interacts with DISC1, a known schizophrenia suscepti-
bility gene, and has also been implicated in Asperger
syndrome, as discussed elsewhere.
2 Thus, there is no
sharp demarcation line separating functionally neutral
polymorphisms and clinically relevant CNVs, and dis-
tinguishing them is not a trivial task (see below). 
Linkage mapping 
X-linked disorders are easily recognizable because of
their characteristic pattern of inheritance. This is why
they are over-represented in OMIM, and why the under-
lying molecular defect has been elucidated in many
Clinical research
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Figure 1. Strategies for the elucidation of monogenic disorders. CGH, comparative genome hybridization; SNP, single-nucleotide polymorphism
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Autosomal dominant disorders also run in families, if
they are not lethal in early life, or are so severe that
affected individuals do not reproduce. For this reason,
they are also easily identifiable, which explains why so
many of them are known. In contrast, autosomal reces-
sive disorders are likely to be under-represented,
because in Western populations, most patients are iso-
lated cases; the monogenic nature of these disorders is
thus not recognized, as discussed above. 
Homozygosity mapping in large, consanguineous fami-
lies is the strategy of choice for mapping recessive dis-
orders (Figure 1c). Such families are common in pre-
dominantly Islamic countries of the “consanguinity
belt”
24 that extends from Morocco into India.
Significantly elevated miscarriage rates and a two-to-
threefold higher prevalence of MR and congenital mal-
formations in these countries are generally ascribed to
malnutrition and poor standards of hygiene. However,
there is evidence that these disorders are also more com-
mon in Muslim families living abroad, such as Turkish
families in Germany and families from Pakistan in the
UK, which suggests that recessive gene defects are
another important cause.
Specific forms of autosomal recessive MR (ARMR)
that are due to primary microcephaly have been inves-
tigated by homozygosity mapping in consanguineous
families from Pakistan and India, which led to the iden-
tification of 7 loci and 5 microcephaly genes.
25-27
Similarly, large-scale homozygosity mapping in consan-
guineous Iranian families has revealed numerous novel
loci and several new genes for nonsyndromic ARMR,
which is thought to be more common than syndromic
forms.
28-31 These studies showed that nonsyndromic
ARMR is extremely heterogeneous, thereby refuting
earlier speculations that, analogous to the fragile X syn-
drome in X-linked MR and to connexin 26 mutations in
nonsyndromic deafness (eg, see ref 32), there might be
frequent forms of this disorder. There is recent evidence,
however, that ARMR is not quite as heterogeneous as
previously suggested. Systematic homozygosity map-
ping and mutation screening in 250 Iranian families has
identified numerous new loci for ARMR and several
allelic mutations in the relevant genes (Kuss, Kahrizi,
Tzschach, Najmabadi, Ropers et al, unpublished).
Analogous studies have also greatly expanded our
knowledge of recessive defects in other diseases such as
deafness, and there is now evidence that recessive forms
also exist in autism and other frequent disorders that
are considered to be multifactorial.
Identification of functional candidate genes 
Many of the clinically relevant deletions detected by
array CGH are larger than 1 to 2 Mb, and most linkage
intervals are even larger, often comprising several hun-
dred genes. This renders mutation screening of all genes
in these intervals very time-consuming and costly.
Numerous software packages have been developed,
including PosMed, Endeavour, and Polyphen (see ref 2)
that can be employed to identify and prioritize func-
tional candidate genes corresponding to the relevant dis-
ease phenotype. The utility of these programs depends
on the specificity of the phenotype; not unexpectedly,
their performance is still relatively poor for nonsyn-
dromic MR, but much better for easily recognizable syn-
dromes. Undoubtedly, it will improve once more is
known about regulatory pathways and the interaction
partners of genes and proteins. 
As mutation detection techniques are rapidly evolving,
sometimes either functional or positional information
may suffice for finding specific gene defects. For exam-
ple, fine-tuning of synaptic transmission is essential for
proper brain function, and there are about 1200 proteins
that are expressed predominantly in the synapse. Even
with conventional Sanger sequencing techniques, screen-
ing of all synapse proteins to isolate gene defects respon-
sible for brain dysfunction is no longer an impossible
task,
33 and novel technologies are around the corner,
which will further facilitate large-scale mutation screen-
ing (see below). 
Why not search for the mutation directly? 
In a recent attempt to identify nearly all genes involved
in X-linked MR in one sweep, an international consor-
tium has employed Sanger sequencing to screen 208
families with X-linked MR for mutations in more than
700 fully annotated X-chromosomal genes.
10This heroic
effort has revealed recurrent truncating mutations in 9
novel XLMR genes, and, notably, also almost 1000 mis-
sense changes. Some of these are allelic and probably
functionally relevant, eg, there are several such muta-
tions in the IQSEC2 gene, which codes for a guanine
nucleotide exchange factor.
34 Recent follow-up studies
revealed apparently pathogenic CNVs in >10% of the
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35 but for more than half of the families studied,
the causative molecular defect is still unknown. 
This pioneering study has highlighted the possibilities,
but also some of the problems, that researchers will face
when trying to identify a single pathogenic mutation in
an entire genome full of mostly neutral sequence vari-
ants. As shown by two independent studies,
36,37 the cod-
ing portion of individual genomes contains approxi-
mately 10 000 nonsynonymous nucleotide changes, even
after excluding those that are known as single-nucleotide
polymorphisms (SNPs). These figures should dampen
the enthusiasm of those proposing to elucidate unknown
monogenic disorders by whole-genome sequencing of
single patients and their healthy parents, using exon
enrichment and next-generation sequencing techniques
(Figure 1d),
3 even though, admittedly, some of the under-
lying defects may be detectable in this way, depending
on the nature of the relevant mutation.
There are now various efficient methods for the enrich-
ment of exons or defined genomic intervals, including
custom-made oligonucleotide arrays, commercial enrich-
ment kits based on hybridization in solution, or
advanced PCR-based techniques (for details, see the
recent review by Tucker et al
38). Preparative chromo-
some sorting and next-generation sequencing
39 is
another attractive alternative for facilitating mutation
detection when the chromosomal location of the defect
is known. An advantage of this approach is that it will
allow us to detect mutations everywhere on the relevant
chromosome, including introns and intergenic sequences.
Moreover, sequencing of sorted chromosomes yields a
more even coverage than other enrichment strategies
that involve PCR amplification (Chen, Wrogemann, Hu,
Haas, Ropers et al, unpublished).
Each of these methods has its limitations, however, and
the same holds for next-generation sequencing techniques
with their usually small read length, which is a problem
for (re)sequencing of repeat-rich genome segments. Still,
in combination, genome partitioning methods and next-
generation sequencing techniques are a great asset for the
detection of mutations in defined genomic intervals, which
has been one of the stumbling blocks for the large-scale
elucidation of single gene disorders.
Conclusions and outlook
With the implementation of these novel methods, the
stage is set for the systematic identification of single
gene defects, which is overdue and will have far-reach-
ing implications for health care. Recessive disorders
likely represent the bulk of the disorders that are hith-
erto unknown, but they are easily overlooked in indus-
trialized countries because most of the patients will be
isolated cases, particularly those without clearly distin-
guishable phenotypes. Their identification and recruit-
ment is much easier in countries where large families
and parental consanguinity are common, but due to
more urgent problems, like the scarcity of clean drink-
ing water, malnutrition, or high perinatal and infant mor-
tality, the diagnosis, prevention, and therapy of single
gene defects is not high on their agenda, even though
these disorders are even more common in these coun-
tries than they are in outbred Western populations. This
argues for collaborations between emerging and indus-
trialized countries, as exemplified by the long-standing
collaboration between our group and an effective
Iranian partner, which was instrumental in the elucidat-
ing the gene defects responsible for several recessive
forms of MR, thereby paving the way for the diagnosis,
prevention and—eventually—therapy of these disorders. 
So far, recessive disorders are considered too rare to jus-
tify carrier screening, but this is likely to change as soon
as there is a reliable and inexpensive test for all reces-
sive disorders. According to leading manufacturers,
“third-generation” sequencing technologies that enable
sequencing of the entire human genome for less than
$5000 US will be on the market by the end of 2010 or
early in 2011, which indicates that carrier tests for all
known recessive disorders will be available sooner
rather than later. Indeed, the (US) National Center for
Genome Resources has recently teamed up with the
Beyond Batten Disease Foundation to develop such a
test for approximately 448 single gene defects using
available next-generation sequencing technology. With
such a carrier test at hand, premarital screening can be
offered to rule out the possibility that both spouses are
heterozygous for defects in the same gene, and preven-
tion programs can be set up, similar to the successful pre-
vention of Tay-Sachs disease in Ashkenazim, which was
initiated in the 1970s.
40
Whole genome sequencing (WGS) is not only the
method of choice for the large-scale elucidation of
Mendelian disorders, but it is also a superior alternative
for risk factor screening in complex diseases, because it
is not fraught with the inherent limitations of GWAS.
2,41
There is no doubt that there exist genetic factors which
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disease manifestation, as discussed for CNVs that are
risk factors for MR, autism, and schizophrenia. Another
telling example is a deletion on chromosome 1q that
seems to be a necessary but not sufficient prerequisite
for thrombocytopenia/absent radius syndrome.
42 CNVs
predisposing for disease can only be identified efficiently
by large case-control studies; attempts to find them by
investigating the normal variation, ie, by excluding all
CNVs present in healthy individuals, are bound to fail
because risk factors for common disorders will be found
in the healthy controls, too. From the health care point
of view it is unfortunate, therefore, that large sums were
invested to generate inventories of normal CNVs,
instead of focusing on disease-relevant CNVs right from
the start—and the same criticism applies to the even
more costly “1000 genome project,” which uses GWS to
study the normal genome variation in 1000 healthy indi-
viduals.
It is a commonly held view that mild forms of MR are
multifactorial, while severe forms are largely due to cat-
astrophic genetic defects, including chromosomal aber-
rations and mutations of single genes. Lehrke
6,7 assumed
that MR genes and genes determining the IQ were iden-
tical, and others speculated that risk factors for mild MR
might be allelic variants of these genes,
43,44 exerting a
moderate effect on the IQ. As the number of MR genes
is increasing, and in view of the novel methods for high-
throughput mutation detection, everything seems to be
in place for putting these ideas to the test.   ❏
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Los trastornos por un gen único vuelven a
estar en el foco de la investigación
A comienzos de los años 1990, cuando se escribió la
segunda fase de cinco años del Proyecto del Genoma
Humano –el cual ha requerido más dinero que cual-
quier otro proyecto de investigación en biología-  los
trastornos comunes fueron presentados como los
blancos futuros de la investigación del genoma. Esta
fue una medida ingeniosa para asegurar un finan-
ciamiento público continuo para este esfuerzo, el
cual se había justificado previamente por las pers-
pectivas que conducirían al diagnóstico, la preven-
ción y el tratamiento de los trastornos Mendelianos,
que si bien son graves ocurren con escasa frecuencia.
Hoy día, después de más de quince años y luego de
haber gastado billones de dólares en los estudios de
asociación del genoma completo (EAGC), se han
identificado muy pocos factores de riesgo genético
importantes para las enfermedades comunes, y el
entusiasmo por grandes EAGC está disminuyendo. Al
mismo tiempo, hay un renovado interés en el estu-
dio de trastornos por un gen único, los cuales son
considerados ahora por algunos investigadores como
una mejor pista para la comprensión de las enfer-
medades comunes. Aunque esto es probablemente
cierto, los trastornos Mendelianos también son
importantes por derecho propio, ya que ellos deben
ser mucho más comunes de lo que generalmente se
piensa. Como se discute aquí, existen varias estrate-
gias eficientes para aclarar los defectos de un gen
único y su aplicación sistemática en combinación con
nuevas técnicas de división del genoma y de secuen-
ciación paralela masiva, tendrán efectos de gran
alcance para los cuidados en salud.  
Les maladies monogéniques attirent à 
nouveau  l’attention
Au début des années 90, lorsque le second plan
quinquennal du projet du génome humain (Human
Genome Project) (plus dispendieux que tout autre
projet de recherche précédent en biologie) a été
écrit, les maladies courantes furent présentées
comme la future cible de la recherche sur le
génome. C’était une manœuvre intelligente desti-
née à s’assurer d’un soutien publique prolongé
pour cette tentative, préalablement justifié par la
perspective du diagnostic, de la prévention et du
traitement des maladies mendéliennes sévères mais
rares pour la plupart. Aujourd’hui, après plus de 15
ans et des milliards de dollars dépensés pour des
études d’association sur le génome entier (GWAS
pour Genome-Wide Association Studies), très peu
de facteurs majeurs de risque génétique pour les
maladies courantes ont été identifiés et l’enthou-
siasme pour les grandes études d’association faiblit.
Au même moment, il existe un regain d’intérêt
pour  l’étude des maladies monogéniques, consi-
dérées maintenant par certains comme une
meilleure piste pour la compréhension des maladies
courantes. C’est probablement le cas, d’autant que
les maladies mendéliennes sont elles-mêmes impor-
tantes puisque beaucoup plus fréquentes qu’on ne
le pense généralement. Dans cet article, nous exa-
minons les différentes stratégies efficaces pour
comprendre les anomalies monogéniques et leur
application systématique en association aux nou-
velles techniques de partition du génome et de
séquençage parallèle massif. Ces stratégies auront
des implications considérables pour la Santé.
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